U.S. Congress - Blog Articles for S.1695 Biologics Price Competition and Innovation Act of 2007
S.1695 - Biologics Price Competition and Innovation Act of 2007
A bill to amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, to promote innovation in the life sciences, and for other purposes. view all titles (2)
All Bill Titles
- Short: Biologics Price Competition and Innovation Act of 2007 as introduced.
- Official: A bill to amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, to promote innovation in the life sciences, and for other purposes. as introduced.
This Bill currently has no wiki content. If you would like to create a wiki entry for this bill, please Login, and then select the wiki tab to create it.
- Newest First
- Oldest First
- Highest Rated
Sort By
S. 1695, A bill to amend the Public Health Service Act to ...
S. 1695 would amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and it would promote innovation in the life sciences....
Bill Action: Introduced: S. 1695: A bill to amend the Public ...
Sen. Edward Kennedy [D-MA] introduced S. 1695: A bill to amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, to promote innovation in the life sciences, and for other purposes. ...
GovTrack: Senate Record: AUTHORITY FOR COMMITTEES TO MEET (110 ...
S. 1695: Biologics Price Competition and Innovation Act of 2007. Last Action: Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably. ...
S. 1695, A bill to amend the Public Health Service Act to ...
1695 would amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and it would promote innovation in the life sciences.......
Senate Committee Passes Biologics Legislation
By Donald Zuhn -- Last week, the US Senate Committee on Health, Education, Labor Pensions announced that it had passed the Biologics Price Competition and Innovation Act. According to a Committee press release, the bill (S. 1695) ...
Support for BioGenerics Legislation Is Falling Apart at the Seams
Although neither the full Senate, nor the House Energy and Commerce Committee have passed similar legislation, it was widely speculated that S. 1695 (or similar legislation) would be considered in the conference committee established to ...
Update on Follow-on Biologics
In July, the Senate Health, Education, Labor and Pensions HELP Committee gave the thumbs up to the Biologics Price Competition and Innovative Act of 2007 (S. 1695), which lays out a pathway for approving the development of follow-on ...
Harvesting Low-Hanging Innovation Fruit False Economy
Also on the docket are the Biologics Price Competition and Innovation Act of 2007 (S. 1695) and The Patent Reform Acts of 2007. More on intellectual property protection and what it means for drug companies and biobiz in CEO of BIO Holds ...
News/ general information
Generics want lowering of the 12-year exclusivity period in S. 1695 in exchange for providing a period of ânew useâ exclusivitywhile Innovator companies want to stick with the 12-year period agreed to under S. 1695. ...
Biosimilars: a market coming of age?
The Biologics Price Competition and Innovation Act of 2007 (S. 1695, or BPCIA), is the first to command significant bi-partisan support. In particular, Orrin Hatch is one of the sponsors of the new bill. This is an important move; ...
OpenCongress - U.S. Congress - H.R.1650 Railroad Antitrust ...
Bills targeted include: Climate change (S.2191), CAFE (H.R.5560, S.2555), Biogenerics Legislation (S.1695 et al), Railroad Antitrust Enforcement (H.R.1650, S.772), Ban Asbestos etc. Act (H.R.3339) ââ¬â for other quarters, see individual ...
US Congress Acts on Follow-On Biologics and FDA Funding ...
In late June, the Senateâs Health, Education, Labor, and Pensions (HELP) Committee voted in favor of the Biologics Price Competition and Innovation Act of 2007 (S. 1695), which will address the scientific, regulatory, and legal issues ...
Biologics Legislation Faces Unresolved Issues.
By Baltazar Gomez -- We previously reported on the passage by the US Senate Committee on Health, Education, Labor & pensions of bill S.1695, entitled "The Biologics Price Competition and Innovation Act of 2007. ...
Biologics Legislation Faces Unresolved Issues
Biologics Legislation Faces Unresolved Issues By Baltazar Gomez -- We previously reported on the passage by the U.S. Senate Committee on Health, Education, Labor & pensions of bill S.1695, entitled "The Biol
OpenCongress - U.S. Congress - S.2555 Reducing Global Warming ...
Bills targeted include: Climate change (S.2191), CAFE (HR5560, S.2555), Biogenerics Legislation (S.1695 et al), Railroad Antitrust Enforcement (HR1650, S.772), Ban Asbestos etc. Act (HR3339) ââ¬â for other quarters, see individual links. ...
Agreement on biosimilars emerges - - Managed Healthcare Executive
Last year, leading senators developed a compromise follow-on biologics bill (S. 1695), but got stuck over language defining an exclusivity period for innovator therapies. Several biosimilar bills have been introduced in the House, ...
CBO Savings Estimate for Follow-On Biologics Underscores Need for ...
... June 25, 2008) - Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement regarding the Congressional Budget Office (CBO) report issued today projecting cost savings from S. 1695, ...
CBO: Biogenerics Would Save Federal Government $6.6 Billion Over ...
Enacting S. 1695 would reduce total expenditures on biologics in the. United States Hidden List by $25 billion over the 2009-2018. period. -- Enacting the bill would reduce budget deficits (or increase surpluses) ...
S. 1695, Biologics Price Competition and Innovation Act of 2007
Cost estimate for the bill as ordered reported by the Senate Committee on Health, Education, Labor, and Pensions on June 27, 2007.
Cost savings from follow-on biologics
Enacting S. 1695 would reduce total expenditures on biologics in the United States by $0.2 billion over the 2009-2013 period and by about $25 billion over the 2009-2018 period. (Over that 10-year period, such savings would equal roughly ...
CBO: Biogenerics Would Save Federal Government $6.6 Billion Over ...
Enacting S. 1695 would reduce total expenditures on biologics in the United States by $25 billion over the 2009- 2018 period. · Enacting the bill would reduce budget deficits (or increase surpluses) by a total of $6.6 billion over the ...
Congressional Budget Office - S. 1695, Biologics Price Competition ...
S. 1695, Biologics Price Competition and Innovation Act of 2007. June 25, 2008. Cost estimate for the bill as ordered reported by the Senate Committee on Health, Education, Labor, and Pensions on June 27, 2007 ...
PCMA » CBO: Biogenerics Would Save Federal Government $6.6 Billion ...
Enacting S. 1695 would reduce total expenditures on biologics in the United States by $25 billion over the 2009- 2018 period. Enacting the bill would reduce budget deficits (or increase surpluses) by a total of $6.6 billion over the ...
The Hill Blog» Blog Archive » Budget Estimate Confirms Biosimilar ...
The Congressional Budget Office (CBO) released a cost estimate yesterday of the âBiologics Price Competition and Innovation Act of 2007,â S. 1695, which the HELP Committee approved last year. CBO estimates that, if Congress enacts S. ...
PhRMA Issues Statement on Follow-On Biologics Legislation
âPhRMA thinks the cost estimate released by the Congressional Budget Office (CBO) of S. 1695 shows that it is possible to deliver cost savings to patients and the government through introduction of follow-on biologics while maintaining ...
CBO Savings Estimate for Follow-On Biologics Underscores Need for ...
... Budget Office (CBO) report issued today projecting cost savings from S. 1695, the Biologics Price Competition and Innovation Act of 2007: The CBO report shows that developing a pathway to review and approve follow-on biologics...
CBO: Biogenerics Would Save Government $6.6 Billion Over Decade
Enacting S. 1695 would reduce total expenditures on biologics in the United States Hidden List by $25 billion over the 2009-2018 period. -- Enacting the bill would reduce budget deficits (or increase surpluses) by a total of $6.6 ...
Biogenerics Would Save How Much? // Pharmalot
The bills, by the way, are S. 1695, the Biologics Price Competition and Innovation Act of 2007; H.R. 1956, the Patient Protection and Innovative Biologic Medicines Act of 2007; and H.R. 5629, the Pathway for Biosimilars Act. If you go ...
CBO: Biogenerics Would Save Federal Government $6.6 Billion Over ...
Enacting S. 1695 would reduce total expenditures on biologics in the United States Hidden List by $25 billion over the 2009-2018 period. â Enacting the bill would reduce budget deficits (or increase surpluses) ...
CBO Savings Estimate for Follow-On Biologics, Biotechnology ...
"By relying on the provisions in S. 1695, the CBO study also shows that we can achieve meaningful cost savings in biologics spending while providing needed protections to allow for continued innovation. H.R. 1956, the Patient Protection ...
Bill's Views
- Today: 0
- Past Seven Days: 10
- All-Time: 978
-%
Users Support Bill
in favor / opposed-
Share This Bill
More Share via Email
